Apiam Animal Health Limited Overview
Apiam Animal Health is Australia's largest rural and regional veterinary group. It combines a business-to-consumer network of companion, mixed, dairy and equine clinics (the Clinical Vet Services segment, roughly 75–78% of revenue) with a business-to-business Intensive Animal Vet Services arm that serves commercial beef feedlots and piggeries (roughly 22–25%). Its differentiator is vertical integration: veterinary consulting sits alongside product procurement and wholesaling, on-farm logistics, ACE Laboratories diagnostics, custom/autogenous vaccine manufacture and genetics, so Apiam captures margin across the animal-health value chain in regional Australia. Between FY21 and FY23 it rolled up roughly 20 regional practices, shifting the mix away from cyclical production-animal work toward resilient pet and mixed-animal care. Earnings conversion lagged revenue growth, a founder-CEO transition followed in June 2025, and Adamantem took the business private in February 2026. It now serves as a mid-market private-equity platform for regional veterinary consolidation.
Company's own description (latest annual report, paraphrased). In its FY22 and FY23 annual reports, Apiam describes itself as providing veterinary products and services to production, companion and equine animals. It serves animals throughout their life cycle through:
-
herd-health systems, production advice, and disease-prevention consulting and products;
-
technologies for compliance with pharmaceutical-use legislation and animal-welfare compliance advice;
-
retail animal-health product sales and on-farm delivery through its own logistics capability;
-
third-party auditing of industry quality-assurance programs, and animal-health technology development;
-
genetics sales and delivery, on-farm and online training, and companion-animal veterinary services.
The financial statements characterise the Group as vertically integrated, with strategic sourcing of products, custom vaccine manufacture, in-house laboratory services and its own on-farm logistics. The company's purpose statement is "to enrich the lives of animals, people and communities".
Independent characterisation. Apiam is best understood as two businesses under one roof.
-
Clinical Vet Services (B2C). This segment was called "Dairy & Mixed Animal" until FY24. It is a regional and peri-urban network of general-practice clinics serving dogs, cats, horses, dairy herds and mixed farm animals. Revenue comes from consultations, procedures, diagnostics, prescription (Schedule 4) pharmaceuticals and over-the-counter products, plus subscription-style programs:
-
Best Mates, an annual pet wellness membership;
-
ProDairy, a herd-health program for dairy farmers. Equine practices and ACE Laboratories diagnostics also sit in this segment.
-
-
Intensive Animal Vet Services (B2B). This segment covers beef feedlot and pig veterinary consulting, data-led production consultancy, product supply, custom vaccines, logistics and genetics, delivered to commercial operators under ongoing service relationships. It is more cyclical: feeder steer inductions, pig herd numbers and disease events such as Japanese Encephalitis in 2022 drive its revenue.
Revenue model mix. The FY23 statutory revenue note splits revenue into goods transferred at a point in time and services transferred over time:
The mix has moved steadily toward services because acquisitions added clinic-based service revenue. Subscription revenue (Best Mates, ProDairy) is a growing but undisclosed fraction; Best Mates had about 11,300 members at FY24 (+32.4% year on year, FY24 release). Apiam has no licensing revenue.
Value-chain position. Apiam sits downstream of the global animal-health manufacturers (Zoetis, Elanco, Boehringer Ingelheim, MSD Animal Health and others) and of wholesale distributors. It acts as prescriber, dispenser, service provider and, in production animals, as procurer and logistics provider to the farm gate. Its own custom vaccine and laboratory capability gives it a modest upstream presence.
Customer types and end-markets.
-
Pet owners in regional towns and peri-urban growth corridors.
-
Equine owners and the thoroughbred breeding sector.
-
Dairy farmers.
-
Mixed farmers (sheep and beef).
-
Commercial beef feedlots and pig producers.
-
Exporters requiring pre-export diagnostics. This was the source of ACE Laboratories' former dairy-heifer-export-to-China revenue, which collapsed in FY25.
No single client or buying group exceeded 10% of revenue in FY22 or FY23 (annual report risk sections).
Strategy
Evolution of stated strategy:
-
IPO strategy (2015). Build "Australia's leading fully integrated rural animal health company". Extend the vertically integrated pig and feedlot model into beef and dairy, and pursue strategic acquisitions.
-
Accelerated Growth (FY22–FY23). Target pro-forma revenue above A$300m by FY24 by:
-
executing the acquisition pipeline;
-
growing organically through Best Mates and ProDairy rollout;
-
opening greenfield clinics in regional growth hubs. The deliberate aim was to shift the mix toward the less cyclical dairy and mixed animal segment. The board stated it would direct all capital to the strategy rather than dividends. Outcome: the target was missed by a wide margin; FY24 revenue was A$204.8m.
-
-
Operational efficiency (FY24). Introduced a vet-supported clinic management model and redundancy programs (Jun and Dec 2023) cutting non-veterinary roles. The company also slowed M&A, focused on free cash flow and debt reduction, and reinstated dividends. Its workforce strategy included:
-
"Your Vet Career, Your Way" flexible careers program;
-
a HECS student-debt reduction offer;
-
compressed working weeks, taken up by ~80% of vets;
-
a 66% full-time vet share against an industry average of 50%.
-
-
Strategic Reset Program (from June 2025, under Interim MD Bruce Dixon):
-
A Business Improvement Team of experienced clinic-running vets and business managers supporting clinic leaders.
-
Intensified clinic performance oversight, with more frequent KPI monitoring and accountability, initially targeting lower-quartile clinics to lift revenue and EBITDA margins.
-
Head Office right-sizing, with redundancies in June–July 2025 expected to save A$1.5m a year from FY26 and clinics assuming greater operational responsibility.
-
Portfolio pruning: exits from Agnes Banks, Hastings and the US JV. Management estimated the Agnes Banks and Hastings exits reduce revenue by ~A$2.3m and increase EBIT by ~A$1m a year.
-
Medium-term guidance. No numerical guidance was given after the abandonment of the A$300m FY24 target. The FY25 release said only that the Strategic Reset was "expected to deliver better revenue and earnings outcomes in FY26". It also cited structural tailwinds: the cohort of pets acquired during COVID in FY20–FY21 reaching middle and senior years within three years.
Products & Services
Apiam is a services business, so the "catalogue" consists of service programs, laboratory and manufacturing capabilities, and distributed products. Pricing is not publicly disclosed unless stated.
Clinical Vet Services
| Offering | Description / capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Companion animal general practice | Consultations, vaccination, surgery, dentistry, diagnostics, in-clinic pharmacy and retail across regional and peri-urban clinics | Dog and cat owners | Expanded heavily FY21–FY23 via acquisitions and greenfields | Fee-for-service plus product margin |
| Best Mates | Annual all-inclusive pet wellness membership (preventive care bundled into a subscription) | Pet owners | Developed in-house; ~11,300 members at FY24, +32.4% YoY | Annual subscription (price not disclosed) |
| Mixed animal practice | Combined companion and livestock (sheep, beef) services in rural towns | Rural households and farmers | Core legacy offering | Fee-for-service |
| ProDairy | Herd-health program covering cow health, welfare, fertility and production | Dairy farmers | Developed in-house; Apiam's flagship dairy program | Subscription-style program |
| Equine services | Equine practices including the Victorian Equine Group, Hunter Equine, Scenic Rim, and the South West Equine JV; covers sport, leisure and thoroughbred breeding work | Horse owners, stud farms | Built FY21–FY23. Agnes Banks Equine Clinic divested Mar 2025 | Fee-for-service |
| ACE Laboratories | Veterinary diagnostic laboratory, including pre-export testing; diverse recurring customer base | Clinics, farmers, exporters | Revenue −54.7% in FY25 after the China dairy-heifer export suspension | Per-test fees |
| Vetriage | Virtual after-hours triage by experienced vet nurses; cut after-hours calls to vets by more than 70% | Apiam clients and vets | Operating by FY23 | Internal capability |
| Greenfield clinics | New clinics in growth corridors (e.g. Yarrawonga VIC, Caboolture QLD), using a refined lower-cost ramp-up model introduced in FY22 | Pet owners | 3 opened FY21–FY22; 3 opened in FY23 | — |
Intensive Animal Vet Services
| Offering | Description / capabilities | Target customer | Status |
|---|---|---|---|
| Beef feedlot veterinary services | Herd health, disease prevention, welfare compliance and data-led production consultancy | Commercial feedlots | At IPO, expected to serve ~50% of the beef feedlot sector. Strong recovery from Q2 FY24 |
| Pig (swine) veterinary services | Herd health, biosecurity, disease surveillance and production consulting | Commercial piggeries | Hit by Japanese Encephalitis in 2022; recovered from H2 FY23 |
| Technology and data analytics | Benchmarking databases, herd-management software, health-management apps, telemedicine/remote video. Described as a key driver of intensive margins | Feedlots, piggeries | Ongoing investment; product-tech leverage cited in the FY25 plan |
| Third-party QA auditing and compliance tools | Audits of industry quality-assurance programs; pharmaceutical-use compliance technology | Producers | Ongoing |
| Training | On-farm and online training programs | Producer staff | Ongoing |
Ancillary / vertically integrated capabilities
| Offering | Description | Status |
|---|---|---|
| Custom (autogenous) vaccines | In-house custom vaccine manufacture. Three new vaccines introduced by FY22. A$700k grant (Mar 2022) for a viral vaccine laboratory in Bendigo targeting emerging pathogens, with phased completion expected by 2025 | — |
| Genetics | Porcine semen and artificial insemination (AI facility in Victoria leased from a Richards-related entity); sheep and goat genetics via All Stock (acquired 2017) | Ongoing |
| Wholesale and procurement | Strategic sourcing of veterinary pharmaceuticals and products | Ongoing |
| Warehousing and logistics | Own on-farm delivery fleet; warehouses at IPO in Bendigo, Toowoomba, Welshpool and Smithton | Ongoing |
| Retail and e-commerce | General animal-health products sold online and in clinic | Ongoing |
| Xtend21® | Long-acting antimicrobial surface/skin protectant based on Zoono Microbe Shield technology, distributed in the US through Aurora Pharmaceutical Inc. | Early-stage launch (FY22). A$2.4m sanitiser/surface-protectant inventory write-down in FY23 indicates commercial underperformance |
Financial Narrative
Sources by year:
-
FY21: FY22 Annual Report comparatives and FY21 release.
-
FY22: FY22 Annual Report.
-
FY23: FY23 Annual Report.
-
FY24: FY24 release (23 Aug 2024) plus FY25 release comparatives.
-
FY25: FY25 release (27 Aug 2025).
-
FY24–FY25 balance-sheet and cash-flow lines are aggregator-sourced (TipRanks/Stockopedia/Alphaspread) unless labelled otherwise.
Income statement
Notes:
-
FY21 reported NPAT was restated from A$5.1m to A$5.0m for provisional acquisition accounting (FY22 AR Note 4).
-
FY23 underlying figures exclude a A$0.92m deferred-revenue adjustment, a A$(0.19)m earn-out reversal and the A$2.4m inventory write-down.
-
The H1 FY25 underlying EBITA was A$8.6m and underlying NPATA A$3.9m. Full-year FY25 underlying EBITA and NPATA were not separately disclosed in the release retrieved.
-
FY25 reported NPAT includes the A$4.5m pre-tax Agnes Banks Equine Clinic impairment.
Margins and growth
Revenue CAGR FY21–FY25: 13.2% per year (A$126.2m to A$207.6m; analyst calculation). Organic growth was low single-digit, and most of the CAGR was acquired (~A$67m of acquisition cash FY21–FY24).
Commentary. The five-year record shows a clear arc of acquisition-led top-line expansion followed by stalled earnings conversion.
FY21–FY23: acquisition phase: - Revenue grew 52% in two years.
-
Gross margin climbed nine points as the mix shifted toward clinic services, where gross profit counts only inventory costs and excludes vet labour.
-
Operating expenses grew faster: FY22 opex +41.6% against revenue +24.6%. Drivers were business-support build-out (people and culture, IT, WHS), recruitment of experienced vets, greenfield ramp-up losses (~A$1.0m EBITDA drag in FY22) and wage inflation (+8.7% like-for-like in Dairy & Mixed in FY23).
-
Reported EBIT therefore fell from A$8.1m (FY21) to A$6.9m (FY23) despite revenue rising A$66m.
-
Finance costs roughly tripled to A$3.8m as net debt rose to A$68.7m and rates rose.
FY24: recovery year: - The June and December 2023 redundancy programs (A$2.6m targeted savings) and a vet-supported clinic management model lifted underlying EBITA 23.2% to A$15.8m.
-
Like-for-like operating expenses fell 2.5%.
-
Reported NPAT more than doubled to A$4.9m against an FY23 base that carried the write-down.
FY25: stall: - Revenue grew only 1.4%.
-
Clinical revenue fell 2.2% on ACE Laboratories (−54.7%), equine softness (−5.4%) and lower-quartile clinic underperformance.
-
Intensive grew 13.1%; because intensive work carries lower gross margins, group gross profit was flat at A$137.6m.
-
Reported EBITDA still rose 5.2% on cost control.
-
The A$4.5m Agnes Banks impairment cut NPAT to A$0.8m.
-
Return on equity collapsed to below 1%, which set the stage for the founder's exit and the Adamantem bid.
Balance sheet
Notes:
-
FY24 and FY25 total assets, equity and cash are aggregator figures (TipRanks). FY25 goodwill is from Alphaspread (aggregator).
-
FY24 and FY25 total bank borrowings are analyst-derived as company net debt plus cash; they include equipment finance of A$4.3m (FY24) and A$4.1m (FY25) that is reported within lease liabilities.
-
FY22 goodwill is the restated A$113.3m from FY23 AR Note 4.
Commentary. Intangibles nearly doubled from A$95m to A$164m between FY21 and FY23, driving net tangible assets per share deep into negative territory (−A$0.26 at FY23). This is a classic roll-up balance sheet, in which equity value rests on goodwill whose recoverability depends on clinic-level margins. The A$4.5m Agnes Banks impairment in FY25 was the first meaningful goodwill-related write-down.
Working capital thinned from A$8.9m to A$1.5m, and the current ratio fell below 1.0 by FY24 (aggregator: 0.96 at FY24 and 0.95 at FY25). That was manageable for a cash-generative services business but left little buffer.
Net debt peaked at A$71.1m (31 Dec 2023) and was paid down to A$63.1m by FY25. Leverage on the covenant measure fell from 3.0x to 2.3x against a 3.5x covenant.
Cash flow
Notes:
-
FY24 and FY25 OCF, capex and FCF are aggregator figures (TipRanks). FY24–FY25 capex is derived as OCF less FCF.
-
FY25 had no acquisitions disclosed; divestment proceeds were not disclosed.
-
Cash conversion ratios are company-reported (FY22 AR, FY23 AR).
Commentary. Operating cash flow was the steadiest part of the story, rising every year from FY21 to FY24. Reported cash conversion above 100% of pre-AASB 16 underlying EBITDA flatters slightly, because lease principal payments of A$4.8m in FY23 sit in financing cash flows. After deducting lease principal, "true" FY23 free cash flow was about A$4.4m (analyst calculation).
Acquisition spend of A$72.4m over FY21–FY23 far exceeded internally generated free cash flow. It was funded by A$26m of equity and roughly A$32m of incremental net debt. When acquisitions stopped (FY24–FY25), free cash flow went to debt reduction and the reinstated 2.0 cps dividend.
Ratios
ROE, ROA, ROIC, debt/equity, coverage and turnover are analyst calculations from the figures above. Leverage multiples are company-reported. FY24–FY25 current ratios are aggregator figures. The cash conversion cycle was not publicly disclosed.
Commentary. Return metrics never approached a credible cost of capital. ROIC peaked below 5% and fell to roughly 2.6% by FY23 (analyst estimate), which is the core reason the market rated the stock below A$0.60 for most of 2023–2025 despite revenue doubling since FY20.
Interest coverage compressed sharply in FY23 to 1.8x on a reported EBIT basis before partially recovering. Covenant leverage was the binding constraint on further M&A, and its approach to 3.0x in FY23 forced the pivot to "organic and margin". Asset turnover stayed broadly flat at ~0.8–0.9x, implying that acquired clinics were bought at multiples that the existing revenue base could not quickly earn back.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Management View) Overview
| Segment (management view) | Contents | Business model |
|---|---|---|
Clinical Vet Services (formerly Dairy & Mixed Animal) | 66 clinics (FY24); companion animal, mixed animal, dairy, equine clinics; Best Mates; ProDairy; ACE Laboratories diagnostics; Vetriage after-hours triage | B2C |
Intensive Animal Vet Services (Beef Feedlot + Pigs) | Feedlot and piggery veterinary consulting, data analytics, product supply, custom vaccines, genetics, logistics | B2B |
Segment revenue (AUD Mn, derived)
| Segment revenue (AUD Mn, derived) | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Clinical Vet Services / Dairy & Mixed (AUD Mn) | 75.7 | 109.8 | 148.5 | 159.7 | 155.7 |
Intensive Animal Vet Services — Feedlot + Pigs (AUD Mn) | 50.5 | 47.2 | 44.3 | 45.1 | 51.9 |
Group revenue (AUD Mn) | 126.2 | 157.2 | 192.8 | 204.8 | 207.6 |
Segment share of revenue (%)
| Segment share of revenue (%) | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Clinical Vet Services share (%) | 60 | 70 | 77 | 78 | 75 |
Intensive Animal Vet Services share (%) | 40 | 30 | 23 | 22 | 25 |
Segment YoY growth (%)
| Segment YoY growth (%) | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Clinical Vet Services reported growth (%) | 23.7 | 45.1 | 35.2 | 7.4 | -2.2 |
Clinical Vet Services like-for-like growth (%) | — | 9.0 | 4.9 | -1.6 | — |
Intensive Animal Vet Services reported growth (%) | -11.4 | -6.5 | -6.1 | 2.3 | 13.1 |
Sub-business FY25 vs FY24 Details
| Sub-business FY25 vs FY24 | Change (%) |
|---|---|
Companion & mixed animal clinics revenue | 1.1 |
Equine clinics revenue | -5.4 |
ACE Laboratories diagnostics revenue | -54.7 |
Dairy revenue | 0.0 |
Clinical Vet Services operating expenses | -3.0 |
Statutory segment profit (AUD Mn)
| Statutory segment profit (AUD Mn) | FY22 | FY23 |
|---|---|---|
Revenue from external customers (AUD Mn) | 157.1 | 191.8 |
Segment operating costs (AUD Mn) | 145.5 | 182.5 |
Segment adjusted operating profit before tax (AUD Mn) | 11.5 | 9.3 |
Segment operating margin (%) | 7.3 | 4.8 |
Income Statement and Per-Share Data
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Revenue — statutory (AUD Mn) | 126.2 | 157.1 | 191.8 | 204.8 | 207.6 |
Revenue — underlying (AUD Mn) | 126.2 | 157.2 | 192.8 | 204.8 | 207.6 |
Gross profit — reported (AUD Mn) | 71.1 | 97.4 | 122.2 | 137.3 | 137.6 |
Gross profit — underlying (AUD Mn) | 71.1 | 97.4 | 125.3 | 137.3 | 137.6 |
EBITDA — reported, post AASB 16 (AUD Mn) | 14.5 | 16.3 | 17.1 | 24.5 | 25.8 |
EBITDA — underlying, post AASB 16 (AUD Mn) | 15.2 | 18.3 | 21.0 | — | — |
EBITDA — underlying, pre AASB 16 (AUD Mn) | — | — | 16.6 | 20.3 | 21.0 |
EBITA — underlying (AUD Mn) | — | 11.5 | 12.8 | 15.8 | — |
EBIT — reported (AUD Mn) | 8.1 | 7.9 | 6.9 | — | — |
Finance costs (AUD Mn) | 1.2 | 1.6 | 3.8 | 5.5 | — |
Pre-tax income (AUD Mn) | 7.0 | 6.5 | 3.2 | — | — |
NPATA — underlying (AUD Mn) | — | 7.1 | 6.4 | 7.2 | — |
NPAT — underlying (AUD Mn) | 5.8 | 6.7 | — | — | — |
NPAT attributable to members — reported (AUD Mn) | 5.0 | 4.6 | 2.3 | 4.9 | 0.8 |
EPS basic (A$ cents) | 4.18 | 3.42 | 1.30 | — | — |
EPS diluted (A$ cents) | 4.13 | 3.36 | 1.28 | — | — |
Dividends per share declared (A$ cents) | 2.4 | 1.6 | 0.0 | 2.0 | 2.0 |
Margin Analysis (%)
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Gross margin — underlying (%) | 56.3 | 62.0 | 65.0 | 67.0 | 66.3 |
Reported EBITDA margin (%) | 11.5 | 10.4 | 8.9 | 12.0 | 12.4 |
Underlying EBITDA margin post AASB 16 (%) | 12.0 | 11.6 | 10.9 | — | — |
Underlying EBITDA margin pre AASB 16 (%) | — | — | 8.6 | 9.9 | 10.1 |
Underlying EBITA margin (%) | — | 7.3 | 6.7 | 7.7 | — |
Reported EBIT margin (%) | 6.4 | 5.0 | 3.6 | — | — |
Net margin — reported (%) | 4.0 | 2.9 | 1.2 | 2.4 | 0.4 |
Revenue growth — reported (%) | 6.6 | 24.6 | 22.6 | 6.2 | 1.4 |
Balance Sheet and Per-Share Data
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 157.3 | 199.0 | 246.0 | 255.8 | 255.8 |
Cash & equivalents (AUD Mn) | 2.2 | 2.8 | 3.2 | 1.8 | 2.5 |
Borrowings — current (AUD Mn) | 2.8 | 2.9 | 2.9 | — | — |
Borrowings — non-current (AUD Mn) | 34.9 | 39.2 | 66.1 | — | — |
Total bank borrowings (AUD Mn) | 37.7 | 42.1 | 69.0 | 68.6 | 65.6 |
Lease liabilities — total (AUD Mn) | 17.3 | 21.3 | 29.0 | — | — |
Net debt — company definition, ex leases (AUD Mn) | 37.2 | 41.0 | 68.7 | 66.8 | 63.1 |
Total equity (AUD Mn) | 80.8 | 108.7 | 117.9 | 122.0 | 121.1 |
Intangible assets incl. goodwill (AUD Mn) | 95.3 | 126.8 | 163.6 | — | — |
Goodwill (AUD Mn) | 86.5 | 113.3 | — | — | 147.0 |
Total current assets (AUD Mn) | 33.3 | 35.9 | 34.7 | — | — |
Total current liabilities (AUD Mn) | 24.4 | 28.8 | 33.3 | — | — |
Working capital (AUD Mn) | 8.9 | 7.1 | 1.5 | — | — |
Net tangible assets per share (AUD) | -0.11 | -0.11 | -0.26 | — | — |
Cash Flow and Margin Analysis (%)
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | 13.7 | 15.0 | 17.4 | 18.9 | 17.6 |
Capex — PP&E (AUD Mn) | 4.7 | 4.3 | 7.9 | 4.9 | 6.8 |
Capex — intangibles (AUD Mn) | 0.2 | 0.5 | 0.4 | — | — |
Free cash flow — OCF less capex (AUD Mn) | 8.7 | 10.2 | 9.2 | 14.0 | 10.8 |
Lease principal payments (AUD Mn) | 2.9 | 3.5 | 4.8 | — | — |
Acquisitions incl. earn-outs, cash (AUD Mn) | 11.7 | 28.2 | 32.5 | 6.3 | 0.0 |
Dividends paid, cash (AUD Mn) | 1.9 | 2.4 | 0.7 | — | — |
Equity raised (AUD Mn) | 6.0 | 20.2 | 0.0 | 0.0 | 0.0 |
Share buybacks (AUD Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Cash conversion — OCF / underlying EBITDA pre AASB 16 (%) | — | 117 | 129 | — | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
ROE — NPAT / average equity (%) | 6.8 | 4.9 | 2.0 | 4.1 | 0.7 |
ROA — NPAT / average total assets (%) | 3.3 | 2.6 | 1.0 | 2.0 | 0.3 |
ROIC — EBIT x 0.7 / (equity + net debt) (%) | 4.8 | 3.7 | 2.6 | — | — |
Current ratio (x) | 1.37 | 1.25 | 1.04 | 0.96 | 0.95 |
Bank debt / equity (x) | 0.47 | 0.39 | 0.59 | 0.56 | 0.54 |
Net debt / underlying EBITDA — covenant basis (x) | 2.0 | 1.9 | 3.0 | 2.6 | 2.3 |
Interest coverage — EBIT / finance costs (x) | 6.8 | 5.0 | 1.8 | — | — |
Interest coverage — underlying EBITA / finance costs (x) | — | 7.2 | 3.4 | 2.9 | — |
Asset turnover — revenue / average total assets (x) | 0.84 | 0.88 | 0.86 | 0.82 | 0.81 |
Geographic revenue (AUD Mn)
| Geographic revenue (AUD Mn) | FY23 | FY24 | FY25 |
|---|---|---|---|
Australia (AUD Mn) | 192.8 | 204.8 | 207.6 |
Rest of world (AUD Mn) | 0.0 | 0.0 | 0.0 |
Share Price
| Metric | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 |
|---|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.75 | 0.52 | 0.46 | 0.96 | 0.685 | 0.51 |
Share Price & Returns
| Reference point | Price (AUD) | Note |
|---|---|---|
IPO price (Dec 2015) | 1.00 | Day-one high A$1.32 |
Undisturbed price before the Adamantem approach (15 Aug 2025) | 0.535–0.54 | Business News Australia / Stockhead |
Close on announcement day (18 Aug 2025) | 0.775 | Intraday high A$0.81 |
Final trading price (6 Feb 2026) | 0.875 | Cum special dividend |
Kroll valuation range | 0.77–0.93 | Independent Expert's Report |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Equity value (AUD Mn) | ~165 | A$0.88 x ~187.9m shares |
Enterprise value ex leases (AUD Mn) | ~228 | Equity plus FY25 net debt of A$63.1m |
EV / Sales (x) | ~1.1 | FY25 revenue A$207.6m |
EV / Underlying EBITDA pre AASB 16 (x) | ~10.9 | FY25 A$21.0m |
EV / Reported EBITDA post AASB 16 (x) | ~8.8 | FY25 A$25.8m (lease-adjusted EV would be higher) |
P / E reported (x) | ~200 | FY25 NPAT A$0.8m (distorted by impairment) |
P / B (x) | ~1.36 | FY25 equity A$121.1m |
Per-Share Data
| Metric | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
Dividends per share declared (A$ cents) | 1.6 | 1.6 | 1.6 | 1.6 | 2.4 | 1.6 | 0.0 | 2.0 | 2.0 | 10.0 |
Debt profile
| Debt profile | Detail |
|---|---|
Listed era | NAB senior facilities, terms extended Aug 2023 to January 2026; covenant net debt/EBITDA ≤3.5x; FY25 leverage 2.3x; equipment finance A$4.1m |
Post-buyout | A$180m+ senior secured credit facilities (Barings co-lead arranger, Mar 2026). Tenor, pricing, covenants and drawn amount not publicly disclosed |
Analyst Conclusions
Management guidance. The last public guidance (FY25 release, Aug 2025) was qualitative: better revenue and earnings in FY26 from the Strategic Reset, supported by A$1.5m of Head Office savings and ~A$1m of annualised EBIT from divestments. Industry tailwinds cited were rising pet-care demand, veterinary technology and the ageing COVID-pet cohort. No numerical FY26 guidance was given, and consensus forecasts are not publicly disclosed. As a private company, Apiam no longer publishes results; FY26 (year to 30 June 2026) results are not publicly disclosed.
Bull case:
-
Margin recovery is mechanical, not heroic. Two programs already delivered results: the FY24 reset lifted underlying EBITA 23.2% on 6.2% revenue growth, and the June 2025 reset removes A$1.5m of overhead. Combined with ~A$1m from divestments and the removal of listed-company costs, pre-AASB 16 underlying EBITDA could move from A$21.0m toward the mid-A$20m range without revenue heroics. That is material against the ~A$228m EV paid.
-
The intensive franchise is cycling up. Beef feedlot and pig revenue grew 13.1% in FY25 after years of decline (−11.4% FY21, −6.5% FY22). Data-led consulting is lifting margins in a B2B niche where Apiam serves a large share of feedlots.
-
PE ownership enables accretive consolidation. In a fragmented regional market, an A$180m+ debt package and an established integration infrastructure (built at heavy cost in FY22) allow tuck-ins at small-practice multiples, below the ~11x pre-AASB 16 EBITDA paid for Apiam.
Bear case:
-
The roll-up never earned its cost of capital. ROIC stayed below 5%, FY25 ROE was 0.7%, and the integration record includes an impairment. Layering LBO leverage on a business whose interest cover fell to 1.8x on reported EBIT in FY23 raises execution and refinancing risk.
-
Clinical Vet Services is losing momentum. Like-for-like revenue was −1.6% in FY24 and the segment fell −2.2% in FY25. Equine is in structural softness, and ACE Laboratories lost half its revenue to a single policy decision. The COVID-pet tailwind is a forecast, not yet evidence.
-
Labour is the binding constraint. Employee costs are ~43% of revenue, and wage growth (8.7% like-for-like in FY23) outran pricing. Regional vet scarcity limits both organic growth and the productivity of acquired clinics.
Key catalysts and monitorables (next 12 months):
-
Appointment of a permanent CEO, and the composition of the Adamantem-era board.
-
First disclosures of post-acquisition M&A (tuck-in clinics or production-animal consultancies) and any rebranding or platform combination.
-
FY26 performance relative to Strategic Reset targets, if disclosed via lender or press channels.
-
Feedlot cattle on-feed numbers and pig herd trends; any resumption of China dairy heifer exports, which would restore ACE Laboratories revenue.
-
Vet workforce policy and any regulatory scrutiny of veterinary pricing.
-
Refinancing or repricing activity on the Barings-led facilities.
-
Outcome for scrip-electing former shareholders (24% HoldCo minority) and any eventual exit (trade sale or re-IPO) on a 3–5 year PE horizon.
Concluding analyst verdict.
Apiam's decade as a listed company is a cautionary case study in regional veterinary consolidation. The strategic logic was sound. Apiam reshaped a cyclical, production-animal-heavy business into one where roughly three-quarters of revenue comes from resilient companion, mixed and dairy clinics. Revenue grew at a 13.2% CAGR from FY21 to FY25, gross margins expanded by eleven points, and operating cash flow rose consistently.
Execution of the "Accelerated Growth" phase, however, destroyed per-share returns. Operating costs outpaced revenue, the debt-funded acquisition spree met rising rates, and the A$300m revenue target was missed by almost a third. Reported EPS fell from 4.18 cents in FY21 to 1.30 cents in FY23. By FY25 the company earned A$0.8m on A$207.6m of revenue, and its market value hovered near book despite a goodwill-dominated balance sheet.
Against that backdrop, the Adamantem transaction was a rational outcome for public shareholders. The A$0.88 headline price represented a 63% premium to the undisturbed price and sat inside Kroll's A$0.77–0.93 range. Shareholders approved it almost unanimously. IPO investors nonetheless realised essentially nominal capital return over ten years once dividends are counted.
For the private owner, the investment case is credible but not low-risk. Underlying EBITDA of roughly A$21m (pre-AASB 16) offers clear self-help levers: overhead removal, divestment of loss-makers, lower-quartile clinic remediation and an intensive segment in cyclical upswing. A fragmented regional market supports accretive tuck-ins. Offsetting this, an A$180m+ secured debt package against that earnings base implies leverage well above the listed-era 2.3x, and the vet labour constraint has not eased.
Apiam is now best viewed as a turnaround-and-platform private-equity asset. Its success will depend less on market growth than on disciplined clinic-level operations — the very capability the listed company struggled to demonstrate. Verdict: strategically well-positioned, operationally unproven; outcome hinges on management execution under leverage.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education |
|---|---|---|---|---|
Bruce Dixon | Interim Managing Director (from 5 Jun 2025); NED from 22 Oct 2024 | 2024– | CEO of Spotless Group Holdings (2012–2015) and Healthscope (to 2010); founder and Chair of Australian Venue Co (sold to KKR 2017, then to PAG 2024); NED of Greencross (2011–12) and Ruralco (2012–14); Executive Director of Linen Services Australia | — |
Matthew (Matt) White | Chief Financial Officer | KMP from at least FY20 (rights granted Mar 2020) | — | — |
Brian Scutt | Chief Operating Officer | — | Long-tenured Apiam executive | — |
Renee Waters | Chief People Officer | KMP from FY23 | — | — |
Dr Chris Richards | Founder; CEO & MD to 5 Jun 2025 | 1998–2025 | Founded the business in 1998; Director of the Fur Life Foundation | BSc, BVSc, MAICD |
Eryl Baron | Company Secretary (as at FY23) | — | 20+ years as company secretary to ASX-listed companies | AGIA |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Background | Education |
|---|---|---|---|---|
Prof. Andrew Vizard | Independent Non-Executive Chairman; IBC member | Since IPO (2015) | Principal Fellow, Faculty of Veterinary & Agricultural Sciences, University of Melbourne; former Director of The Mackinnon Project; ex-director of Animal Health Australia, PrimeSafe and the Australian Wool Corporation; Chair of the Vizard Foundation | BVSc (Hons), MVPM, FAICD |
Richard (Rick) Dennis | Independent NED; Chair of Audit & Risk; IBC member | Pre-FY21 | 35+ years at EY, twice Managing Partner of EY Queensland, Deputy COO/CFO of EY Asia-Pacific; chair/director roles at AF Legal, Motorcycle Holdings, ERA, Cettire, Step One | BComm, LLB |
Evonne Collier | Independent NED; IBC member | 1 Oct 2022 | Chair of Curae Health; NED of 4DMedical; ex-NED of 1300Smiles and Think Childcare; corporate background in strategy, marketing and digital turnarounds | BA, MBus, GradCertAppFin, GAICD |
Dr Jan Tennent | Independent NED; Chair of Remuneration & Nomination (FY23) | Nov 2020 | — | PhD, BSc (Hons), GCertMgt, GAICD, FTSE, FASM |
Bruce Dixon | NED, then Interim MD | 22 Oct 2024 | See above | — |
Diggory Howitt | Director (an Appendix 3Y change-of-interest notice lodged 25 Aug 2025 indicates directorship) | — | — | — |
Michael van Blommestein | Former NED | Retired 24 Nov 2022 | Ex-VP and Country Manager ANZ, Zoetis; ex-President of Animal Medicines Australia | GAICD |
Directors' Remuneration
| KMP (FY23) | Salary & fees (AUD) | Cash bonus (AUD) | Share-based (AUD) | Total (AUD) |
|---|---|---|---|---|
Dr Chris Richards — MD | 431,915 | 0 | 15,475 | 595,673 |
Matthew White — CFO | 291,649 | 0 | 12,307 | 347,512 |
Brian Scutt — COO | 244,215 | 0 | 9,575 | 268,911 |
Renee Waters — CPO | 219,143 | 0 | 9,926 | 258,437 |
Prof. Andrew Vizard — Chair | 140,000 | 0 | 0 | 140,000 |
Richard Dennis — NED | 80,000 | 0 | 0 | 80,000 |
Dr Jan Tennent — NED | 70,000 | 0 | 0 | 70,000 |
Evonne Collier — NED (part year) | 47,511 | 0 | 0 | 52,500 |
Michael van Blommestein — NED (part year) | 26,146 | 0 | 0 | 28,891 |
Total KMP | 1,550,579 | 0 | 47,283 | 1,841,924 |
Directors' Remuneration (Annual)
| KMP total remuneration trend (AUD K) | FY21 | FY22 | FY23 |
|---|---|---|---|
Total KMP remuneration (AUD K) | 1,340 | 1,515 | 1,842 |
MD total remuneration (AUD K) | 455 | 505 | 596 |
Major Shareholders
| Holder | Stake | Note |
|---|---|---|
Dr Chris Richards (founder) | 38.65m shares (~19.9–21% of issued capital) | FY23 AR; Adamantem held a call option over 19.9%, exercisable only on a rival bid |
Other directors combined (FY23) | <0.5m shares | FY23 AR |
Top 10 institutional holders | Not publicly disclosed in sources retrieved | — |
Shareholder count | ~1,555 holders (per chair's comment at the scheme meeting) | Mayne Report, Feb 2026 |
Current (post-23 Feb 2026) | 100% held by Pepper Bidco Pty Ltd; Pepper Holdco owned by Adamantem Capital Fund II plus electing former shareholders (65 holders electing scrip on ~40.8m shares; scrip capped at 24% of HoldCo) | Scheme announcements; Mayne Report |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Ownership | Revenue / scale | Relative positioning vs Apiam |
|---|---|---|---|---|
VetPartners (Australia) | Companion, mixed, rural clinics | Private / PE-backed | Not publicly disclosed; IBISWorld ranks it the largest market-share holder | Largest consolidator; absorbed National Veterinary Care (late 2019, ~A$250m per Stockhead); strongest direct competitor for regional clinic M&A |
Greencross Vets (with Petbarn) | Companion clinics | Private (PE; delisted 2019) | — | Metro/suburban companion leader; integrated pet retail; limited production-animal presence |
Petstock Vet | Companion clinics in retail | Majority-owned by Woolworths Group | — | Retail-anchored vet expansion, including regional towns |
National Veterinary Care (legacy) | Companion, regional | Part of VetPartners | — | Historic ASX peer |
Independent regional mixed practices | Mixed, dairy, equine | Private owners | Fragmented | Apiam's main local competitors and acquisition targets |
Specialist equine hospitals (e.g. Scone Equine Group) | Equine | Private | — | Premium equine referral; Hunter Valley overlap |
Production-animal consultancies (feedlot and pig specialist vets) | Intensive | Private | — | Compete for B2B consulting; Apiam's scale and integration are advantages |
Veterinary wholesalers (e.g. Covetrus, other distributors) | Product supply to farms and clinics | Private / multinational | — | Compete with Apiam's wholesale and logistics arm |
Commercial veterinary laboratories (e.g. IDEXX, other private labs) | Diagnostics | Listed (IDEXX) / private | Not publicly disclosed for Australia | Compete with ACE Laboratories |
Animal health manufacturers' vaccines (Zoetis, Elanco, Boehringer Ingelheim, MSD) | Vaccines | Listed / private multinationals | Global scale | Primarily suppliers; their commercial vaccines substitute for Apiam's custom vaccines |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Apiam (FY25) | VetPartners AU | Greencross | Petstock Vet |
|---|---|---|---|---|
Revenue (AUD Mn) | 207.6 | — | — | — |
Revenue growth (%) | 1.4 | — | — | — |
Gross margin (%) | 66.3 | — | — | — |
Underlying EBITDA margin, pre AASB 16 (%) | 10.1 | — | — | — |
R&D intensity (%) | Not disclosed (<0.5 proxy) | — | — | — |
Ownership | PE (Adamantem) | PE | PE | Corporate (Woolworths) |
Production-animal exposure | High (~25% plus dairy) | Moderate | Low | Low |
“—” = not publicly disclosed.
Recent Developments
The 18-month window (Apr 2025 – Oct 2026) is extended back to Oct 2024 for context.



